Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) independent directors’ relevant independent opinions on the matters of the 28th meeting of the seventh board of directors I. prior approval opinions on the acquisition of 100% equity and related party transactions of Guangdong Shaxi Pharmaceutical Co., Ltd
Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) submitted relevant details on the acquisition of 100% equity of Guangdong Shaxi Pharmaceutical Co., Ltd. after careful verification and based on independent judgment, we believe that this equity acquisition of the company is the demand for the long-term development of the company’s traditional Chinese medicine industry, is conducive to the company’s improvement of the competitiveness and comprehensive strength of traditional Chinese medicine business, and is in line with the company’s long-term development strategy; The transaction was conducted by all parties based on the principles of voluntariness, equality, fairness and reasonableness. The transaction pricing was fair and reasonable, without any damage to the interests of the company and minority shareholders, and did not violate the provisions of relevant national laws and regulations. Agree to submit the related party transaction to the board of directors of the company for deliberation. 2、 Independent opinions on the acquisition of 100% equity and related party transactions of Guangdong Shaxi Pharmaceutical Co., Ltd
Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) the acquisition of 100% equity and related party transactions of Guangdong Shaxi Pharmaceutical Co., Ltd. has been approved in advance by us, and was deliberated and adopted at the 28th meeting of the seventh board of directors of the company, and the related directors withdrew from voting. We believe that this related party transaction of the company is necessary for the company’s business integration and long-term operation and development, the approval procedure does not violate the provisions of relevant national laws and regulations, the pricing policy and basis of related party transactions are fair and reasonable, and there is no damage to the interests of the company and investors. Therefore, all independent directors agree to the company’s acquisition of 100% equity of Guangdong Shaxi Pharmaceutical Co., Ltd.
Independent directors: Fan Xiaoping, Shi Ximin, Lu Weiyue December 14, 2021
